Patents by Inventor Kapil Mehta
Kapil Mehta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190105287Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: ApplicationFiled: November 30, 2018Publication date: April 11, 2019Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal
-
Patent number: 10182997Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analog encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analog is administered parenterally in a pharmaceutically acceptable carrier.Type: GrantFiled: March 14, 2016Date of Patent: January 22, 2019Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Aggarwal
-
Publication number: 20180318217Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.Type: ApplicationFiled: June 13, 2018Publication date: November 8, 2018Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal, Lawrence Helson
-
Patent number: 10004687Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.Type: GrantFiled: May 13, 2014Date of Patent: June 26, 2018Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SIGNPATH PHARMA INC.Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal, Lawrence Helson
-
Publication number: 20160193159Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 14, 2016Publication date: July 7, 2016Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Aggarwal
-
Patent number: 9283185Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: GrantFiled: May 27, 2011Date of Patent: March 15, 2016Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal
-
Publication number: 20140322303Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.Type: ApplicationFiled: May 13, 2014Publication date: October 30, 2014Applicants: Board of Regents, The University of Texas System, SignPath Pharma Inc.Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal, Lawrence Helson
-
Patent number: 8784881Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.Type: GrantFiled: December 1, 2007Date of Patent: July 22, 2014Assignees: Board of Regents, The University of Texas System, SignPath Pharma Inc.Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal, Lawrence Helson
-
Patent number: 8765797Abstract: Methods and compounds for treating cancer, dmg resistance and/or metastasis are described herein. These methods and compounds can inhibit the expression of aberrant TG2 expression and/or inhibit the binding of GTP to TG2, and thereby prevent the induction of epithelial to mesenchymal transition of cancer cells, and a stem cell-like phenotype.Type: GrantFiled: June 21, 2011Date of Patent: July 1, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Kapil Mehta, Anupam Kumar, Jansina Fok, Shuxing Zhang
-
Publication number: 20130158087Abstract: Methods and compounds for treating cancer, dmg resistance and/or metastasis are described herein. These methods and compounds can inhibit the expression of aberrant TG2 expression and/or inhibit the binding of GTP to TG2, and thereby prevent the induction of epithelial to mesenchymal transition of cancer cells, and a stem cell-like phenotype.Type: ApplicationFiled: June 21, 2011Publication date: June 20, 2013Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Kapil Mehta, Anupam Kumar, Jansina Fok, Shuxing Zhang
-
Patent number: 8299040Abstract: A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one or more techniques, including, but not limited to, downregulating transglutaminase expression, inhibiting TG2 translation, or blocking TG2 enzymatic activity, such as with a small molecule inhibitor or intracellular antibody (intrabody).Type: GrantFiled: October 5, 2007Date of Patent: October 30, 2012Assignee: Board of Regents, The University of Texas SystemInventors: Kapil Mehta, Amit Verma, Sushovan Guha, Jansina Fok, Gabriel Lopez-Berestein, Anil Sood
-
Publication number: 20110287085Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 27, 2011Publication date: November 24, 2011Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat B. Aggarwal
-
Patent number: 7968115Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: GrantFiled: September 7, 2005Date of Patent: June 28, 2011Assignee: Board of Regents, The University of Texas SystemInventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal
-
Publication number: 20080279844Abstract: A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one or more techniques, including, but not limited to, downregulating transglutaminase expression, inhibiting TG2 translation, or blocking TG2 enzymatic activity, such as with a small molecule inhibitor or intracellular antibody (intrabody).Type: ApplicationFiled: October 5, 2007Publication date: November 13, 2008Inventors: Kapil Mehta, Amit Verma
-
Publication number: 20080138400Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.Type: ApplicationFiled: December 1, 2007Publication date: June 12, 2008Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: RAZELLE KURZROCK, LAN LI, KAPIL MEHTA, BHARAT BHUSHAN AGGARAWAL, LAWRENCE HELSON
-
Publication number: 20080103213Abstract: The present invention provides a compositions and methods for the treatment of Neurofibromatosis Type 1 and 2, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system to target Merlin and proteins of the Merlin pathway. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: ApplicationFiled: October 5, 2007Publication date: May 1, 2008Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: RAZELLE KURZROCK, LAN LI, KAPIL MEHTA, BHARAT AGGARWAL
-
Patent number: 7223397Abstract: The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-trans-retinoic acid (RA) is used to induce high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. CD38 was then used as target for delivering plant toxin (gelonin) to leukemia cells. Treatment of leukemia cells with RA induced high levels of CD38 in those cells that otherwise had low CD38 expression. The RA-induced leukemia cells then became exquisitely sensitive to an immunotoxin constructed from an anti-CD38 monoclonal antibody conjugated to the plant toxin gelonin.Type: GrantFiled: January 7, 1999Date of Patent: May 29, 2007Assignee: Research Development FoundationInventors: Michael Rosenblum, Kapil Mehta
-
Publication number: 20060067998Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: ApplicationFiled: September 7, 2005Publication date: March 30, 2006Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Aggarawal
-
Patent number: 6414115Abstract: The present invention relates to parasitic nematode transglutaminase proteins; to parasitic nematode transglutaminase nucleic acid molecules, including those that encode such transglutaminase proteins; to antibodies raised against such transglutaminase proteins; and to compounds that inhibit parasitic nematode transglutaminase activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic nematodes.Type: GrantFiled: January 13, 1998Date of Patent: July 2, 2002Assignees: Heska Corporation, Board of Regents, The University of Texas SystemInventors: Ramaswamy Chandrashekar, Kapil Mehta
-
Patent number: 6334999Abstract: To optimize the delivery of all-trans retinoic acid to lung tissue, the potential of vehiculating this drug in liposomes and delivering it via aerosol was determined. Liposomes provide a means to prevent local irritation of lung tissue, reduce pulmonary toxicity, prolong therapeutic levels, and generate high drug concentrations at the tumor sites. Therefore, the delivery of ATRA to the lung tissue in mice was accomplished by nebulization of L-ATRA. The liposomes in the aerosol were uniform, stable, and retained the drug well. The drug was effectively delivered at high concentrations to the lungs of mice and was retained at least up to 96 h after a single exposure to L-ATRA aerosols. The aerosol-delivered ATRA was biologically active as demonstrated by its ability to induce the expression of tissue-type transglutaminase. Aerosol delivery of L-ATRA offers an effective way to deliver high levels of ATRA to the lung without apparent pulmonary toxic effects.Type: GrantFiled: August 27, 1999Date of Patent: January 1, 2002Assignee: Research Development FoundationInventors: Brian E. Gilbert, Ranjani Parthasarathy, Kapil Mehta